Topic: multiple sclerosis
Sanofi laid out $125 million to take a stake in two of Denali's RIPK1 inhibitors, and now one will be tested in three tough-to-treat brain disorders.
Capitalizing on a process the body uses to eliminate overly aggressive T cells could be a new way to treat autoimmune diseases.
Royal Philips and Ypsomed plan to install digital, at-home adherence tracking across a line of connected injection and infusion systems.
The decision comes a year after the monoclonal antibody, GNbAC1, failed to beat placebo in a phase 2b trial.
Laquinimod was once hailed as a blockbuster heir to Copaxone but suffered a string of late-phase failures that dragged down Teva.
Active Biotech and Teva delivered more bad news from their clinical development of laquinimod, this time from a phase 2 trial in Huntington’s disease.
A startup exited stealth mode to push a new class of drugs that could help regenerate nerve cells’ insulating myelin sheaths in diseases such as MS.
Octave Biosciences picked up a pair of industry veterans for its board of directors, as well as $14 million to advance its care management technology.
Nadim Ahmed said Celgene’s arm’s-length relationship with the biotech it bought for $7.2 billion three years ago led to a substandard filing.
An FDA refuse-to-file notice delayed Celgene's ozanimod by about a year, but it could have been worse.